Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821117 | 1.00 | KDM4E (0.68) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL3624681 | 1.00 | KDM4E (0.68) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL5307853 | 1.00 | — | — | |
| SCHEMBL7748218 | 0.92 | KDM4E (0.60) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL23014621 | 0.92 | KDM4E (0.60) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL8036117 | 0.89 | KDM4E (0.58) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL15043622 | 0.89 | KDM4E (0.58) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL13654249 | 0.89 | KDM4E (0.58) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL16731723 | 0.89 | KDM4E (0.58) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL20038482 | 0.89 | KDM4E (0.58) | KDM4ETSHRPOLBPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1078 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094950-A | Ligand compound with quinoline structure, and radioactive or non-radioactive marker and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122071508-A | Targeting NPY polypeptide nuclide ligand and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2026-05-22 | — | — | CN | claimed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | C-BIOMEX CO., LTD. (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2026098519-A1 | RADIOLIGAND COMPOUNDS AND USES THEREOF | Chengdu New Radiomedicine Technology Co., Ltd. (CN) | 2026-05-15 | — | — | WO | claimed |
| WO-2026101949-A1 | COMPOUNDS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | RAYZEBIO, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | claimed |
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | PETER MACCALLUM CANCER INST (AU) | 2026-03-19 | — | — | US | claimed |
| EP-3619191-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2020-03-11 | — | — | EP | claimed |
| US-20190083662-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | OXFORD FINANCE LLC | 2019-03-21 | — | — | US | claimed |
| US-20190030194-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2019-01-31 | — | — | US | claimed |
| WO-2018204869-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2018-11-08 | — | — | WO | claimed |
| WO-2018204872-A2 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2018-11-08 | — | — | WO | claimed |
| EP-3294316-A2 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2018-03-21 | — | — | EP | claimed |
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2017-11-16 | — | — | US | claimed |
| WO-2016179529-A2 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-11-10 | — | — | WO | claimed |
| US-9194802-B2 | Luminescent probes having a phenanthridinyl antenna, and methods of use | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-11-24 | — | — | US | claimed |
| US-20140080163-A1 | LUMINESCENT PROBES HAVING A PHENANTHRIDINYL ANTENNA, AND METHODS OF USE | NATIONAL SCIENCE FOUNDATION | 2014-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | KDM4E 4115/4885TSHR 540/4885POLB 3628/4885 |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | KDM4E 1996/4885TSHR 28/4885POLB 2573/4885 |
| US-20190030194-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | SLC7A1, SLC19A1, PAICS | KDM4E 2561/4885TSHR 892/4885POLB 3302/4885 |
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | CCKAR, NPY1R, NPY2R | KDM4E 3098/4885TSHR 117/4885POLB 1489/4885 |
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | CA5A, CA1, CA9 | KDM4E 1685/4885TSHR 1511/4885POLB 2094/4885 |
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | PTH1R, VDR, MEN1 | KDM4E 3345/4885TSHR 166/4885POLB 2042/4885 |
| US-20190083662-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | IGF1R, IGFBP1, IGFBP2 | KDM4E 3656/4885TSHR 36/4885POLB 4141/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | KDM4E 2930/4885TSHR 5/4885POLB 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.